Extreme weight gain in teens. (Clinical Capsules).
In a prospective study of 50 adolescents (46 of whom had schizophrenia), 19 of 21 (91%) patients treated with olanzapine and 9 of 21(43%) treated with risperidone experienced weight gain of 7% or more. Only 1 of 8 (13%) patients treated with haloperidol during the 12-week, in-hospital treatment gained more than 7% of their baseline body weight (J. Am. Acad. Child Adolesc. Psychiatry 41 :33 7-43, 2002).
The rate of weight gain increased the most in the first 4 weeks of treatment and subsequently diminished over the last 8 weeks. By week 12, patients in the olanzapine group gained a mean of 7.2 kg; patients in the risperidone group gained a mean of 3.9 kg; and those in the haloperidol group added a mean of 1.1 kg. By weeks 8 and 12, patients in the olanzapine group gained significantly more weight than those in the risperidone group.
|Printer friendly Cite/link Email Feedback|
|Publication:||Clinical Psychiatry News|
|Article Type:||Brief Article|
|Date:||Apr 1, 2002|
|Previous Article:||St. John's wort extract. (Clinical Capsules).|
|Next Article:||Unipolar depression therapy. (Clinical Capsules).|
|Pediatric weight loss. (Clinical Capsules).|
|Antipsychotic weight gain.|
|Irish Daily Mirror Comment: Stop our kids dying to be thin.|